ストックスクリーナーアプリを入手
28.34
0.60%
-0.17
アフターアワーズ：
28.23
-0.11
-0.39%
前日終値:
$28.51
開ける：
$28.23
24時間の取引高:
2.82M
Relative Volume:
0.45
時価総額：
$3.60B
収益：
当期純損益:
$-472.34M
株価収益率:
-6.8357
EPS:
-4.1459
ネットキャッシュフロー:
$-340.33M
1週間 パフォーマンス:
-3.21%
1か月 パフォーマンス:
-11.38%
6か月 パフォーマンス:
-17.28%
1年 パフォーマンス:
-15.55%
1日の値動き範囲:
$27.91
$28.84
1週間の範囲:
$27.05
$29.06
52週間の値動き範囲:
$25.77
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
28.34 | 3.60B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-28 | 開始されました | Lake Street | Buy |
| 2026-05-27 | 再開されました | Truist | Buy |
| 2026-03-26 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-29 | 開始されました | Canaccord Genuity | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) to Chinese Yuan Price Today | Live VKTX to CNY Converter & Exchange Rate - CryptoRank
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) - CryptoRank
Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months - Yahoo Finance
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
VKTX Advances Obesity Program With New Oral Maintenance Study - Zacks Investment Research
Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87 - AD HOC NEWS
Viking Therapeutics Starts VK2735 Obesity Maintenance Trial - grafa.com
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - Yahoo Finance
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - TradingView
Viking Therapeutics begins oral VK2735 maintenance trial in obesity - Mugglehead Investment Magazine
Viking Therapeutics initiates oral maintenance dosing study - Investing.com
Viking Therapeutics Inc (Derivatives) price today, VKTX to USD live price, marketcap and chart - CoinMarketCap
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - PR Newswire
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - Yahoo Finance
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock - The Motley Fool
Here Are My Top 4 Stocks to Buy in October - The Motley Fool
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTXObesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis - Simply Wall Street
Viking Therapeutics Inc (MIL:1VKTX) Stock Price, Trades & News - GuruFocus
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) - Yahoo! Finance Canada
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? - Yahoo Finance
Prediction: This Stock Could Double Over the Next 5 Years - The Motley Fool
Inventory turnover of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Viking Therapeutics Slides as Financing Overhang Appears to Weigh on Shares - Quiver Quantitative
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - sg.finance.yahoo.com
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - Yahoo Finance
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Therapeutics Raises Capital via Equity and Convertibles - TipRanks
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes - TradingView
Viking Therapeutics raises $575 million in dual offering - Investing.com
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - Morningstar
About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares. - Stock Titan
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross - TradingView
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - Yahoo Finance
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - PR Newswire
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX) - Seeking Alpha
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| MARIANNA MANCINI | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
18,217 |
609,636 |
0 |
| GREG ZANTE | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
21,217 |
710,141 |
0 |
| BRIAN LIAN | Officer |
Jul 29 '26 |
Proposed Sale |
33.32 |
148,517 |
4,947,888 |
0 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
| Aubuchon Neil William | Chief Commercial Officer |
Mar 10 '26 |
Buy |
33.50 |
4,475 |
149,912 |
4,475 |
| MARIANNA MANCINI | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,406 |
0 |
| GREG ZANTE | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,470 |
0 |
| BRIAN LIAN | Officer |
Jan 05 '26 |
Proposed Sale |
32.96 |
233,409 |
7,692,134 |
0 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
5.35%
0.14%
大文字化:
|
ボリューム (24 時間):